Ensysce Biosciences (ENSC) Net Margin (2020 - 2025)
Ensysce Biosciences (ENSC) has disclosed Net Margin for 6 consecutive years, with 756.26% as the latest value for Q3 2025.
- On a quarterly basis, Net Margin fell 77561.0% to 756.26% in Q3 2025 year-over-year; TTM through Sep 2025 was 244.49%, a 6520.0% decrease, with the full-year FY2024 number at 153.3%, up 32309.0% from a year prior.
- Net Margin was 756.26% for Q3 2025 at Ensysce Biosciences, down from 126.39% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 19.36% in Q3 2024 to a low of 3855.62% in Q2 2022.
- A 5-year average of 850.12% and a median of 455.88% in 2023 define the central range for Net Margin.
- Peak YoY movement for Net Margin: soared 534195bps in 2021, then crashed -363616bps in 2022.
- Ensysce Biosciences' Net Margin stood at 662.88% in 2021, then surged by 42bps to 385.21% in 2022, then crashed by -77bps to 680.4% in 2023, then skyrocketed by 60bps to 273.42% in 2024, then plummeted by -177bps to 756.26% in 2025.
- Per Business Quant, the three most recent readings for ENSC's Net Margin are 756.26% (Q3 2025), 126.39% (Q2 2025), and 147.42% (Q1 2025).